Thomas Steyer’s Apogee Therapeutics APGE Stock Holding History

Thomas Steyer’s Portfolio APGE Stock Details APGE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q2	–	Sell	-305,000	Closed	-$20.3M	–	170
2024 Q1	$20.3M	Buy	+305,000	New	+$13.3M	0.09%	74

Other funds holding APGE

VR Adviser New York $3.3B AUM 525.74% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return

Braidwell Stamford, Connecticut $2.7B AUM 88.53% 1-Year Est. Return

DCM

Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return

Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return

FFM

Fairmount Funds Management West Conshohocken, Pennsylvania $1.51B AUM 546.08% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Thomas Steyer's APGE Position: Q2 2024 in Review

Thomas Steyer sold out of Apogee Therapeutics (APGE) in Q2 2024, closing a stake of 305,000 shares — an estimated $20.3M sold.

Thomas Steyer first reported a position in APGE in Q1 2024 and held it in 1 quarter. The position peaked at $20.3M in Q1 2024. 139 funds tracked by Wall St. Rank hold APGE as of Q2 2024.

Thomas Steyer reported no remaining Apogee Therapeutics position as of Q2 2024 after selling out during the quarter.
Thomas Steyer sold 305,000 Apogee Therapeutics shares in Q2 2024, an estimated $20.3M.
Thomas Steyer first reported a position in Apogee Therapeutics in Q1 2024 and held it in 1 quarter.
Thomas Steyer's Apogee Therapeutics position peaked at $20.3M in Q1 2024.
139 funds tracked by Wall St. Rank held Apogee Therapeutics as of Q2 2024.

Based on Farallon Capital Management's 13F filing for Q2 2024, filed 14 Aug 2024.